| Name | Title | Contact Details |
|---|
DENTSPLY International is a leading manufacturer and distributor of dental and other consumable healthcare products. Our broad global product platform helps dental professionals serve patients` oral health care for a lifetime, from preventive services to tooth replacement. DENTSPLY oral health products range from general dental consumables and laboratory products to products supporting the dental specialty markets of orthodontics, endodontics and implants. Our powerful worldwide dental sales force takes our solutions to market around the globe. Now more than 2,800 members strong, our sales team keeps us close to the dental professionals who rely on our product solutions to serve their patients` complete oral health needs. DENTSPLY’s global consumable healthcare product team provides innovative urological and surgical solutions designed to improve the quality of life for users, caregivers, and practitioners. With a presence in more than 120 countries, patients and practitioners virtually everywhere in the world rely on DENTSPLY to deliver dental and healthcare solutions with a strong focus on quality, innovation, and service.
Hannibal Regional Hospital Foundation is a non-profit corporation (501,(c)3) and a part of the Hannibal Regional Healthcare System which exists to support Hannibal Regional Hospital by raising privately donated money.
Medafor is a Minneapolis, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Humans across the globe and of all walks of life want to live at their personal best, and are seeking more natural alternatives to feeling their best and getting the most out of life. Today, they are discovering the answer through natural cannabinoid products. At the same time, science and technology are unlocking the future potential of cannabinoids. We believe that cannabinoids, when used responsibly, have the power to enhance the full spectrum of well-being and to help us live healthier and happier lives. Parallel is improving the well-being of our consumers today through our proprietary, innovative brands, while planting seeds for the future through our robust innovation and high bar for business standards.
Humacyte, Inc. (Nasdaq: HUMA) is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. The Company develops and manufactures acellular tissues to treat a wide range of diseases, injuries and chronic conditions. Humacyte`s initial opportunity, a portfolio of human acellular vessels (HAVs), is currently in late-stage clinical trials targeting multiple vascular applications, including vascular trauma repair, arteriovenous access for hemodialysis, and peripheral arterial disease. Preclinical development is also underway in coronary artery bypass grafts, pediatric heart surgery, treatment of type 1 diabetes, and multiple novel cell and tissue applications. Humacyte`s 6mm HAVs for AV access for performing hemodialysis was the first product candidate to receive the FDA`s Regenerative Medicine Advanced Therapy (RMAT) expedited review designation, and the HAV technology received priority designation for the treatment of vascular trauma by the U.S. Secretary of Defense.